Sat, Feb 28, 2015, 7:38 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

NUO THERAPEUTICS, INC. Message Board

  • lettucecometogether lettucecometogether Mar 24, 2011 11:09 PM Flag

    very promising.

    Cytomedix, Inc. is a biotechnology company developing advanced tissue regeneration technologies. Our primary focus is the utilization of platelets and platelet derivatives to manage wound healing. We are dedicated to improving the lives of patients suffering with chronic wounds. 5-7 million people every year suffer from chronic or complex wounds1 that are typically difficult to heal, and may cause unusual hardship and depression. These wounds can lead to complications such as infection, pain, and limb amputation. Chronic Wounds

    The AutoloGel™ System received marketing clearance (510K) from the FDA in September 2007, with the commercial launch in early 2008. The AutoloGel™ System is intended to be used at point-of-care for the safe and rapid preparation of platelet rich plasma (PRP) from a small sample of the patient’s own blood. The PRP gel produced by the AutoloGel™ System is suitable for exuding wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and for the management of mechanically and surgically debrided wounds. Autologel™ System

    The effectiveness of the AutoloGel™ System is documented in a prospective, multicenter, randomized, controlled study of patients with diabetic foot ulcers. The endpoint of the study was complete wound closure maintained for at least 12 weeks of follow up. Furthermore, clinicians have reported anecdotal evidence of improved outcomes when AutoloGel™ is used in combination with other products such as collagen or antibiotics. Clinical Evidence

    The success of AutoloGel™ is based on a proprietary formulation which utilizes a complex cocktail of proteins, cytokines, and growth factors derived from autologous plasma and platelets. Some of these cytokines and growth factors have been shown to mobilize white blood cells and stem cells, enhance cell proliferation, and/or reduce inflammation. Technology

    In addition to the AutoloGel™ System, Cytomedix is actively developing peptides to fight inflammation and initiate angiogenesis. These products and technologies will be commercialized through a combination of licensing agreements, direct sales and strategic partnerships. Pipeline

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CMXI
0.34-0.01(-2.86%)Nov 13 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.